Oxcia AB (publ) (“Oxcia”) has today published the annual report for 2022.
Press releases
Oxcia AB (publ) publishes interim report fort the first quarter 2023
First quarter (January-March 2023) Operating loss totaled SEK -16,566,375 (-5 313 134). Loss for the period totaled SEK – 16,450,467 (-5 313 134). Cash flow from operating activities totaled SEK – 6,760,934 (-4 993 784). Earnings per share before dilution… Continue reading Oxcia AB (publ) publishes interim report fort the first quarter 2023
Oxcia has been awarded a grant of 3 million SEK for a study in refractory AML patients
In tough competition in Swelife’s and Medtech4Health’s joint call for Collaborative projects for better health in 2022, Oxcia AB has been awarded a grant of 3 million SEK. The call aims to finance the development of innovative and sustainable life… Continue reading Oxcia has been awarded a grant of 3 million SEK for a study in refractory AML patients
Three abstracts on OXC-101 selected for poster presentations at AACR 2023
Oxcia AB (publ) today reports that three abstracts on OXC-101, its clinical candidate for cancer, have been selected for poster presentations at the American Association for Cancer Research (AACRS) Annual meeting held in Orlando, Florida, 14-19[th] April, 2023 . The abstracts concern the clinical safety, further understanding of the broad anti-cancer efficacy and the mechanism of action and will be published in the online Proceedings supplement of the AACR journal Cancer Research.
New pre-clinical study shows that OXC-201 may be a promising treatment for IPF (pulmonary fibrosis)
A new study, “Small-molecule-mediated OGG1 inhibition attenuates pulmonary inflammation and lung fibrosis in a murine lung fibrosis model” (freely translated: Pharmacological OGG1 inhibition reduces acute lung injury and lung fibrosis in mice), was published on January 26 in Nature Communications ( https://doi.org/10.1038/s41467-023-36314-5, L. Tanner, A. B. Single, R. K. V. Bhongir , M. Heusel , T. Mohanty, C. A. Q. Karlsson, L. Pan, C-M. Clausson, J. Bergwik , K. Wang, C. K. Andersson, R. M. Oommen, J. S. Erjefält, J. Malmström, O. Wallner, I. Boldogh, T. Helleday, C. Kalderén & A. Egesten) shows that OXC-201 (TH5487) may be a promising treatment for idiopathic pulmonary fibrosis (IPF).
The EIC has awarded Oxcia AB with a EIC transition grant of 2.5 million Euros for development of OXC-201.
Oxcia is very pleased to announce that the EIC (the European Innovation Council) has selected Oxcia’s OXC-201 to receive an EIC Transition grant of 2.5 million Euros. The EIC is Europe’s flagship innovation programme to identify, develop and scale up… Continue reading The EIC has awarded Oxcia AB with a EIC transition grant of 2.5 million Euros for development of OXC-201.
Oxcia AB publishes Year-End Report for 2022
FOURTH QUARTER (October–December 2022) Operating loss totaled SEK -8,972,042 (-4,190,243). Loss for the period totaled SEK -8,912,366 (-4,190,243). Cash flow from operating activities totaled SEK -9,565,926 (-4,979,465). Earnings per share before dilution totaled SEK -0.41 (-0.21). Earnings per share after… Continue reading Oxcia AB publishes Year-End Report for 2022
Data show OXC-201 may be a promising treatment for allergic asthma.
A new study, Pharmacological OGG1 inhibition decreases murine allergic airway inflammation, was published 17[th] of October in Respiratory pharmacology, Frontiers in Pharmacology, (DOI 10.3389/fphar.2022.999180, Tanner L, Bergwik J, Bhongir RKV, Pan L, Dong C, Wallner O, Kalderén C, Helleday T, Boldogh I, Adner M and Egesten A) and demonstrates that Oxcia’s potential clinical candidate OXC-201 (TH5487) may be a promising treatment for allergic asthma.
Enrolment completed and recommended phase II dose reached for OXC-101
Oxcia AB, today announced that it has completed enrollment and evaluation of the last patient in the MASTIFF Phase I clinical trial of OXC-101 in escalating doses for the treatment of patients with advanced solid malignant tumours. The recommended phase… Continue reading Enrolment completed and recommended phase II dose reached for OXC-101
Oxcia AB is strengthening the organization further
Several exciting pre-clinical and clinical studies are imminent. We are therefore happy that we have been able to recruit two very experienced and competent Scientists. Dr William Stafford has taken up the position as Translational Director from 1st of September.… Continue reading Oxcia AB is strengthening the organization further